Publicacións en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (13)

2025

  1. CDK4/6 inhibitors for metastatic breast cancer in routine clinical practice in Spain: survey of patterns of use and oncologists’ perceptions

    Clinical and Translational Oncology, Vol. 27, Núm. 9, pp. 3819-3826

2024

  1. Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain

    PharmacoEconomics - Open, Vol. 8, Núm. 6, pp. 887-896

  2. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

    Breast Cancer Research and Treatment, Vol. 206, Núm. 2, pp. 317-328

  3. Indicators to evaluate quality of care in head and neck cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 5, pp. 1089-1097

2022

  1. Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study

    Future oncology (London, England), Vol. 18, Núm. 35, pp. 3913-3927

2021

  1. Adherence to the Sociedad Española de Oncología Médica (SEOM) Algorithm for the Treatment of Hyponatremia in Oncology Patients in Spain: The ALGA Study

    Advances in Therapy, Vol. 38, Núm. 1, pp. 290-303

2019

  1. Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP)

    Clinical and Translational Oncology, Vol. 21, Núm. 3, pp. 380-390

  2. Phase I/II trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2

    Journal of Clinical Oncology

2018

  1. Experience with eribulin in patients with breast cancer and cutaneous metastases: Case studies

    Future Oncology, Vol. 14, Núm. 7s, pp. 37-44

  2. Oncologist’s knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study

    Clinical and Translational Oncology, Vol. 20, Núm. 5, pp. 613-618

2016

  1. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 17, Núm. 3, pp. 357-366

2015

  1. Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: Results of the PANCOSTABRAX study

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 15, Núm. 4, pp. 579-589

2014

  1. Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists

    Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 914-920